Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Collaborative Groups / Prostate and Urologic Cancers Research Group
Overview

If you are a member of this group, log in to gain full access.

Upcoming Events

Events coming up for the Prostate and Urologic Cancers Research Group.

No upcoming events.

Projects

Projects undertaken by the Prostate and Urologic Cancers Research Group.

This collaborative group doesn't have any projects.

Biomarkers
KLK4
The glandular kallikreins are a distinct group of serine proteases with molecular masses of 25,000 to 40,000. Kallikreins are a subgroup of serine proteases ...
PCA3
The prostate cancer antigen 3 (PCA3) gene is a highly specific biomarker upregulated in prostate cancer. Because there is no extensive open reading ...
THBS1
TSP is an adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. TSP can bind to fibrinogen, fibronectin, laminin, type V collagen ...
KLK2
The glandular kallikreins are a distinct group of serine proteases with molecular masses of 25,000 to 40,000. The glandular kallikrein gene family comprises 25 ...
KLK11
The glandular kallikreins are a distinct group of serine proteases with molecular masses of 25,000 to 40,000. Kallikreins are a subgroup of serine proteases ...
Projects/Protocols

Projects

There are currently no projects of which this group is a part.

Protocols

A Methylation Panel for Bladder Cancer

PI: Gazdar, Adi

Assay of TMPRSS2:ERG and PCA in Canary PASS

PI: Lin UW, Daniel W.

The identification of biomarkers that, at the time of diagnosis, associate with the presence of, or progression to, aggressive prostate cancer will transform ...

Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer - Supplemental Pre-Validation Protocol

PI: Czerniak, Bogdan

Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement

PI: Anderson, Karen

The overall goal of this project application for the EDRN set-aside funds is to focus our collaborative efforts to identify p53 mutation-specific antibody ...

Biomarker Development Laboratory

PI: Zhao, Yingming

Biomarker Discovery for Renal Cell Carcinoma Through Serum, Urine and Tissue Protein Profiles

PI: Basler, Joseph W.

Biomarkers and clinical parameters associated with Gleason score upgrading

PI: Thompson, Ian M.

Biomarkers for Prostate and Bladder Cancer

PI: Liu, Alvin Y.

CD26+ cancer cells and CD90+ tumor-associated stromal cells were sorted from tumor tissue. Dataset analysis with transcriptomes of CD26+ luminal, CD104+ basal, ...

Body Fluids as a Source of Diagnostic Biomarkers

PI: Semmes, John

Body Fluids as a Source of Diagnostic Biomarkers: Prostate

PI: Semmes, John

Recent advances in high-throughput protein expression profiling of bodily fluids has generated great enthusiasm and hope for this approach as a potent ...

Canary TMA

PI: Nelson, Peter S

This protocol describes a multi-center, retrospective, case-cohort tissue microarray (TMA) study to evaluate tissue biomarkers for their ability to predict ...

Chemokine Prostate Cancer Biomarkers

PI: Macoska, Jill

STUDY DESIGN 1. The need for pre-validation studies. Preliminary data from our laboratory demonstrates a potential utility for CXCL5 and CXCL12 as biomarkers ...

Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection

PI: Liu, Alvin Y.

Tumor-associated stromal cells differ from normal gland-associated stromal cells in gene expression. Genes up-regulated in these stromal cells are potential ...

Detection of Bladder CA by Microsatellite Analysis (MSA)

PI: Schoenberg, Mark P.

Goal 1: To determine sensitivity and specificity of microsatellite analysis (MSA) of urine sediment, using a panel of 15 microsatellite markers, in detecting ...

Development and Clinical Validation of Biomarkers for Prostate Cancer

PI: Partin, Alan W

Development and Evaluation of a Tumor Marker for Prostate Cancer

PI: Partin, Alan W

Major strides in the early detection, staging, monitoring, and risk stratification of men with prostate cancer have been realized over the last few decades. ...

EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge

PI: Chinnaiyan, Arul M.

The goal of this EDRN set-asides proposal is to carry out pre-validation studies on sarcosine as a metabolomic biomarker of prostate cancer in urine. Not only ...

EDRN Pre-Validation of Multiplex Biomarker in Urine

PI: Chinnaiyan, Arul M.

The goal of this proposal is to begin to establish an EDRN “pre-validation” trial of a multiplex set of transcripts, including the ETS gene fusions, in ...

Early Detection of Cancer by Affinity Mass Spectrometry-Set Aside funds

PI: Semmes, John

A.   RATIONALE The recent introduction of multiple reaction monitoring capabilities offers unprecedented capability to the research arsenal available to ...

Early Detection of Urinary Bladder Cancer

PI: Czerniak, Bogdan

Early Molecular Detection of Invasive Bladder Cancer by Urine Examination

PI: Czerniak, Bogdan

Establishment of a serum standard for use in high-throughput proteomic

PI: Semmes, John

Glycoprotein Biomarkers for the Early Detection of Aggressive Prostate Cancer

PI: Zhang, Hui L.

The Early Detection Research Network of the NCI is charged with the discovery, development and validation of biomarkers for early detection and prognosis ...

Identification of protein and genetic biomarkers of prostate cancer and risk factors for progression of disease

PI: Thompson, Ian M.

Inflammation as a Potential Marker of Risk ad Progression for Prostate Cancer

PI: Thompson, Ian M.

Integrated Development of Novel Molecular Markers

PI: Sidransky, David

Methylation & Proteomics-Based Detection of Bladder Cancer

PI: Cairns, Paul

To determine sensitivity and specificity of quantitative real-time methylation specific PCR (qMSP) of urine sediment DNA, using a panel of several methylated ...

Molecular Genetics of Urinary Bladder Carcinoma

PI: Czerniak, Bogdan

Molecular Progression of Methylation in Bladder Cancer

PI: Sidransky, David

Ornithine decarboxylase (ODC) Polymorphism and Breast and Prostate Cancer

PI: Helzlsouer, Kathy

PCA3 Validation Study and Urinary Reference Set

PI: Wei, John

Prostate cancer (PCa) is the third leading cause of cancer-related deaths among United States men, accounting for 33% of such diagnosed cancers.(1) An ...

Pre-Validation of Metabolomic Biomarkers of Prostate Cancer

PI: Chinnaiyan, Arul M.

Prostate Active Surveillance Study

PI: Lin UW, Daniel W.

This is a multi-center, prospective active surveillance study with selective intervention in patients with previously untreated, clinically localized prostate ...

Prostate Rapid Pre-Validation Set

PI: Sanda, Martin

Determine which markers move to validation using the prospectie prostate reference set samples.

Prostate Rapid Reference Set Applicant: Diamandis - Mt Sinai (2006)

PI: Diamandis, Eleftherios P.

Prostate Rapid Reference Set Application: Haab - Van Andel (2006)

PI: Haab, Brian

To evaluate TSP-1 as a marker to specifically detect prostate cancer

Prostate Rapid Reference Set Application: Chan/Beckman Coulter (2007)

PI: Chan, Daniel

Evaluate performance of [-2]proPSA as an early detection marker for prostate cancer

Prostate Rapid Reference Set: Getzenberg - Johns Hopkins (2006)

PI: Getzenberg, Robert H.

Analyze marker EPCA2 on 123 observations (60 prostate cancers and 63 non-prostate cancers)

Prostate Specimen Ref Set Applicant: Isaacs-JHU-2010

PI: Isaacs, William

Can SNP genotyping assist in the prediction of biopsy results for prostate cancer.

Prostate Upgrading Team Project

PI: Thompson, Ian M.

Prostate-Specific Glycoproteins for Early Detection of Prostate Cancer

PI: Zhang, Hui L.

Release of Set Aside Funds - microRNA Biomarkers for Renal Cell Carcinoma

PI: Thompson, Ian M.

SELDI Phase I: Assay Validation-Prostate

PI: Semmes, John

It is then the goal of this collaborative project – EDRN-Prostate-SELDI Investigational Collaboration (EPSIC) - to use state-of-the-art protein profiling ...

SELDI Profiling of serum and urine from patients with urologic disease in support of bladder cancer studies

PI: Semmes, John

SELDI Validation Study Phase II

PI: Semmes, John

This project –A Comprehensive Program for the Validation of Prostate Cancer Early Detection with Novel Protein Identification Techniques -- is divided into ...

San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR)

PI: Thompson, Ian M.

To determine if there are ways to predict which men will get prostate cancer, if there are ways to predict how a prostate cancer will develop (for example, ...

Standard Specimen Reference Set: Prostate

PI: Sanda, Martin

To collect biologic samples on men prior to prostate biopsy, in association with clinical information and common data elements appropriate for evaluation of ...

T2-Erg Team Project

PI: Sanda, Martin

Prostate cancer (PCa) is the third leading cause of cancer-related deaths among United States men, accounting for 33% of such diagnosed cancers.(1) An ...

The Early Detection Research Network: Biomarker Reference Laboratories

PI: Chia, David

The Prostate Tumor Microenvironment Exhibits differentially expressed Genes Useful for Diagnosis

PI: Mercola, Dan

To develop a multi-site prospective clinical validation trial of the multigene diagnostic signature for the diagnosis of prostate cancer from non tumor ...

Using MALDI-IMS and MRM to stablish a pipeline for discovery and validation of tumor neovasculature biomarker candidates.

PI: Gambhir, Sanjiv

In an effort to circumvent the limitations associated with biomarker discovery workflows involving cell lines and cell cultures, histology-directed MALDI ...

Validation of [-2]proPSA for the Early Detection of Prostate Cancer

PI: Chan, Daniel

Primary Objective – To validate the serum %[-2]proPSA marker for the improvement of diagnosis and risk assessment of prostate cancer and reducing unnecessary ...

Data
Biomarkers for Prostate and Bladder Cancer
Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection
EDRN-WHI Pre-Clinical Colon Ca Specimens
MALDI Dilution Data: Randolph
Prostate Rapid Reference Set Applicant: Diamandis - Mt Sinai (2006)
Prostate Rapid Reference Set Application: Haab - Van Andel (2006)
SELDI Phase I: Assay Validation-Prostate
SELDI Validation Study Phase II

Datasets Outside of any Protocol

Calendar

There are no current events.

Past Events

There are no past events.

Documents
 Title   Author   Type   Modified 
File aergaerg Sean Kelly File Nov 30, 2012 12:53 PM
test urology Sean Kelly Page Nov 30, 2012 12:53 PM